Conditions: Smoking
Keywords: smoking lapse behavior smoking cessation varenicline naltrexone medication effect on smoking lapse behavior
Allocation: RANDOMIZED | Intervention model: FACTORIAL
Enrollment: 30
Healthy volunteers: no

Brief summary:
The purpose of this study is to examine how medications thought to attenuate the effects of alcohol (naltrexone) and smoking cessation medications (varenicline) affect the ability to resist smoking and also subsequent ad-lib smoking, following a low-dose alcohol priming drink, in non-treatment seeking alcohol-drinking daily smokers.

Detailed description:

Arms:
arm 1: naltrexone (25mg) + varenicline (2mg) arm 2: varenicline 2mg arm 3: placebo control

Interventions: intervention 1: naltrexone intervention 2: varenicline intervention 3: placebo
Intervention descriptions: intervention 1: 25 mg/day, with 1-week lead-in medication period. The starting dose is 0 mg/day for days 1-3, followed by 12.5mg/day for day 4, followed by 25mg/day for days 5-7, plus during the laboratory session (day 8). intervention 2: 2mg/day, with 1-week lead-in medication period. The starting dose is 0.5mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5, followed by 1.0 mg twice daily for days 6-7, plus during the laboratory session (day 8). intervention 3: placebo

Protocol document: